PHARMAMAR HA OPTADO POR LA RETIRADA DE LA SOLICITUD DE AUTORIZACIÓN DE COMERCIALIZACIÓN DE APLIDIN ( PLITIDEPSIN ) ... WITHDRAWAL OF APPLICATIÓN FOR THE MARKETING AUTHORISATION OF APLIDIN ( PLITIDEPSIN ) JULY 23 , 2025 .
As Findings From DisCoVeRy Show An Absence Of Effect On Late Clínical Status And Mortality, There Is No Reason To Qdvocate Remdesivir Use Outside of Clínical Trials . ...